

# Misako Nagasaka

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/147541/publications.pdf>

Version: 2024-02-01

83  
papers

1,922  
citations

279798

23  
h-index

302126

39  
g-index

83  
all docs

83  
docs citations

83  
times ranked

2215  
citing authors

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer. Expert Review of Anticancer Therapy, 2018, 18, 63-70.  | 2.4  | 172       |
| 2  | KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?. Cancer Treatment Reviews, 2020, 84, 101974.   | 7.7  | 143       |
| 3  | Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC. Journal of Thoracic Oncology, 2021, 16, 740-763.  | 1.1  | 115       |
| 4  | Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01.. Journal of Clinical Oncology, 2020, 38, 9504-9504.   | 1.6  | 91        |
| 5  | Cancer Immunology and Immunotherapy. Anticancer Research, 2016, 36, 5593-5606.  | 1.1  | 69        |
| 6  | EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study. Lung Cancer, 2020, 145, 186-194.  | 2.0  | 68        |
| 7  | Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer. Molecular Cancer Therapeutics, 2021, 20, 2577-2584.   | 4.1  | 66        |
| 8  | Catalog of 5â€™™ Fusion Partners in ALK-positive NSCLC Circa 2020. JTO Clinical and Research Reports, 2020, 1, 100015.  | 1.1  | 62        |
| 9  | Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer. Molecular Cancer, 2021, 20, 82.   | 19.2 | 58        |
| 10 | Liquid Biopsy to Identify Actionable Genomic Alterations. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 978-997.   | 3.8  | 54        |
| 11 | Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC. Lung Cancer, 2021, 158, 126-136.  | 2.0  | 53        |
| 12 | Proposal of Classification Criteria for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis Disease Activity. Frontiers in Microbiology, 2018, 9, 1651.   | 3.5  | 48        |
| 13 | Evidence of NTRK1 Fusion as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC: Results From a Large-Scale Survey of NTRK1 Fusions in Chinese Patients With Lung Cancer. Clinical Lung Cancer, 2020, 21, 247-254.  | 2.6  | 48        |
| 14 | An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor-Resistant Refractory ALK-Positive or ROS1-Positive NSCLC. Journal of Thoracic Oncology, 2020, 15, 1484-1496. | 1.1  | 43        |
| 15 | Targeting KRAS in pancreatic cancer: new drugs on the horizon. Cancer and Metastasis Reviews, 2021, 40, 819-835.  | 5.9  | 41        |
| 16 | Efficacy and safety of zenocutuzumab in advanced pancreas cancer and other solid tumors harboring NRG1 fusions.. Journal of Clinical Oncology, 2021, 39, 3003-3003.   | 1.6  | 37        |
| 17 | KRAS Inhibitors- yes but what next? Direct targeting of KRAS vaccines, adoptive T cell therapy and beyond. Cancer Treatment Reviews, 2021, 101, 102309.   | 7.7  | 37        |
| 18 | Trastuzumab Deruxtecan-Induced Interstitial Lung Disease/Pneumonitis in ERBB2-Positive Advanced Solid Malignancies: A Systematic Review. Drugs, 2022, 82, 979-987.  | 10.9 | 35        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Clinicopathologic Features and Response to Therapy of <i>NRG1</i> Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry. <i>Journal of Clinical Oncology</i> , 2021, 39, 2791-2802.            | 1.6 | 32        |
| 20 | PD1/PD-L1 inhibition as a potential radiosensitizer in head and neck squamous cell carcinoma: a case report. , 2016, 4, 83.   |     | 31        |
| 21 | Thromboembolism in ALK+ and ROS1+ NSCLC patients: A systematic review and meta-analysis. <i>Lung Cancer</i> , 2021, 157, 147-155.   | 2.0 | 30        |
| 22 | Gut microbiome and response to checkpoint inhibitors in non-small cell lung cancer—A review. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 145, 102841.  | 4.4 | 28        |
| 23 | A user's guide to lorlatinib. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 151, 102969.   | 4.4 | 26        |
| 24 | Neuregulin 1 Fusion-Positive NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1354-1359.  | 1.1 | 25        |
| 25 | Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution. <i>Anticancer Research</i> , 2019, 39, 781-790.           | 1.1 | 25        |
| 26 | Will the clinical development of 4th-generation double mutant active-ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK+ NSCLC?. <i>Translational Oncology</i> , 2021, 14, 101191. | 3.7 | 24        |
| 27 | <i>NRG1</i> and <i>NRG2</i> fusion positive solid tumor malignancies: a paradigm of ligand-fusion oncogenesis. <i>Trends in Cancer</i> , 2022, 8, 242-258.  | 7.4 | 24        |
| 28 | Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance. <i>International Journal of Molecular Sciences</i> , 2020, 21, 237.   | 4.1 | 23        |
| 29 | Lorlatinib Should Be Considered as the Preferred First-Line Option in Patients With Advanced ALK-Rearranged NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 532-536.                                 | 1.1 | 23        |
| 30 | <i>NTRK</i> fusion positive colorectal cancer is a unique subset of <i>CRC</i> with high <i>TMB</i> and microsatellite instability. <i>Cancer Medicine</i> , 2022, 11, 2541-2549.                           | 2.8 | 22        |
| 31 | Non-small cell to small cell lung cancer on PD-1 inhibitors: two cases on potential histologic transformation. <i>Lung Cancer: Targets and Therapy</i> , 2018, Volume 9, 85-90.                             | 2.7 | 20        |
| 32 | Unleash the power of the mighty T cells-basis of adoptive cellular therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 136, 1-12.   | 4.4 | 20        |
| 33 | Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial. <i>Clinical Cancer Research</i> , 2022, 28, 2020-2029.          | 7.0 | 18        |
| 34 | A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC). <i>Cancer Treatment Reviews</i> , 2022, 106, 102393.                            | 7.7 | 18        |
| 35 | Cerebrospinal Fluid CXCL10 as a Candidate Surrogate Marker for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis. <i>Frontiers in Microbiology</i> , 2019, 10, 2110.                                | 3.5 | 17        |
| 36 | How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC). <i>Translational Lung Cancer Research</i> , 2020, 9, 2521-2534.                  | 2.8 | 15        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Incidence of Second Primary Lung Cancer After Low-Dose Computed Tomography vs Chest Radiography Screening in Survivors of Head and Neck Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2021, 147, 1071.  | 2.2 | 15        |
| 38 | Spotlight on Sotorasib (AMG 510) for KRASG12C Positive Non-Small Cell Lung Cancer. <i>Lung Cancer: Targets and Therapy</i> , 2021, Volume 12, 115-122.   | 2.7 | 13        |
| 39 | A Novel Sequentially Evolved EML4-ALK Variant 3 G1202R/S1206Y Double Mutation In Cis Confers Resistance to Lorlatinib: A Brief Report and Literature Review. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100116.   | 1.1 | 12        |
| 40 | Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C Mutant Cancers. <i>Cancer Research Communications</i> , 2022, 2, 342-352.  | 1.7 | 12        |
| 41 | The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2022, 23, 52-59.  | 2.6 | 11        |
| 42 | Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer. <i>Lung Cancer: Targets and Therapy</i> , 2021, Volume 12, 133-138.   | 2.7 | 11        |
| 43 | Histologic Transformation in NSCLC with PD-1 therapy. <i>Journal of Thoracic Oncology</i> , 2017, 12, e133-e134.   | 1.1 | 9         |
| 44 | Is this really just "fatigue"? A case series of immune-related central adrenal insufficiency secondary to immune checkpoint inhibitors. <i>Clinical Case Reports (discontinued)</i> , 2018, 6, 1278-1281.  | 0.5 | 9         |
| 45 | Effect of Exposure to Agent Orange on the Risk of Monoclonal Gammopathy and Subsequent Transformation to Multiple Myeloma: A Single-Center Experience From the Veterans Affairs Hospital, Detroit. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 305-311. | 0.4 | 9         |
| 46 | A Catalog of 5 <sup>th</sup> Fusion Partners in ROS1-Positive NSCLC Circa 2020. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100048.  | 1.1 | 9         |
| 47 | Risk Factors Associated with a Second Primary Lung Cancer in Patients with an Initial Primary Lung Cancer. <i>Clinical Lung Cancer</i> , 2021, 22, e842-e850.  | 2.6 | 9         |
| 48 | Role of Molecular Profiling in Diagnosis of Papillary Renal-cell Cancer Presenting as Cancer of Unknown Primary Site. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e713-e717.  | 1.9 | 8         |
| 49 | Amivantamab (JNJ-61186372) induces clinical, biochemical, molecular, and radiographic response in a treatment-refractory NSCLC patient harboring amplified triple EGFR mutations (L858R/ T790M/G796S) in cis. <i>Lung Cancer</i> , 2022, 164, 52-55.                   | 2.0 | 8         |
| 50 | Phase II Trial of Adjuvant Nivolumab Following Salvage Resection in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck. <i>Clinical Cancer Research</i> , 2022, 28, 3464-3472.   | 7.0 | 8         |
| 51 | <i>EGFR</i>-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine: Importance of Germline <i>EGFR</i> T790M Testing. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1188-1192.  | 4.9 | 7         |
| 52 | COPD and lung cancer incidence in the Women's Health Initiative Observational Study: A brief report. <i>Lung Cancer</i> , 2020, 141, 78-81.  | 2.0 | 7         |
| 53 | Identification of Novel CDH1-NRG2 <sup>±</sup> and F11R-NRG2 <sup>±</sup> Fusions in NSCLC Plus Additional Novel NRG2 <sup>±</sup> Fusions in Other Solid Tumors by Whole Transcriptome Sequencing. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100132.        | 1.1 | 7         |
| 54 | STRN-ALK, A Novel In-Frame Fusion With Response to Alectinib. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100125.  | 1.1 | 7         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Responses in patients receiving sequential paclitaxel post progression on PD1 inhibitors. Oral Oncology, 2018, 80, 100-102.   | 1.5 | 6         |
| 56 | Complete response with neoadjuvant avelumab in Merkel cell carcinoma – A case report. Oral Oncology, 2019, 99, 104350.  | 1.5 | 6         |
| 57 | <p>Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in ALK-Rearranged NSCLC: A Report of Two Cases</p>. Lung Cancer: Targets and Therapy, 2020, Volume 11, 13-18.                                    | 2.7 | 6         |
| 58 | PLEKHH2-ALK: A Novel In-frame Fusion With Durable Response to Alectinib: Utilizing RNA Sequencing in Search for Hidden Gene Fusions Susceptible to Targeted Therapy. Clinical Lung Cancer, 2021, 22, e51-e53.   | 2.6 | 6         |
| 59 | Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer. Lung Cancer: Targets and Therapy, 2021, Volume 12, 103-114.  | 2.7 | 6         |
| 60 | Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation. Lung Cancer: Targets and Therapy, 2022, Volume 13, 33-45.  | 2.7 | 6         |
| 61 | Cetuximab and methotrexate in recurrent or metastatic head and neck squamous cell carcinoma – A single institution analysis of 54 patients. Clinical Otolaryngology, 2019, 44, 639-643.   | 1.2 | 5         |
| 62 | Gastrostomy tube dependence and patient-reported quality of life outcomes based on type of treatment for human papillomavirus-associated oropharyngeal cancer: Systematic review and meta-analysis. Head and Neck, 2021, 43, 3681-3696.                   | 2.0 | 5         |
| 63 | Targeting Alternative Splicing as Adjunctive Treatment in EML4-ALK v3a/b+ NSCLC: Knowing Our Socratic Paradox and Learning From Spinal Muscular Atrophy. Journal of Thoracic Oncology, 2022, 17, 182-185.   | 1.1 | 5         |
| 64 | Is NRG2± Fusion a –Doppelgänger– to NRG1±/² Fusions in Oncology?. Journal of Thoracic Oncology, 2020, 15, 878-880.  | 1.1 | 4         |
| 65 | The role of immune checkpoint inhibitors in anaplastic thyroid cancer (Case Series). Oral Oncology, 2020, 109, 104744.  | 1.5 | 4         |
| 66 | Creation and validation of a bladder dysfunction symptom score for HTLV-1-associated myelopathy/tropical spastic paraparesis. Orphanet Journal of Rare Diseases, 2020, 15, 175.   | 2.7 | 4         |
| 67 | &lt;p&gt;A retrospective study evaluating the pretreatment tumor volume (PTV) in non-small cell lung cancer (NSCLC) as a predictor of response to program death-1 (PD-1) inhibitors&lt;/p&gt;. Lung Cancer: Targets and Therapy, 2019, Volume 10, 95-105. | 2.7 | 3         |
| 68 | Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC). Lung Cancer, 2021, 160, 92-98.  | 2.0 | 3         |
| 69 | Immune checkpoint inhibitor-induced pneumonitis: Incidence, clinical characteristics, and outcomes. Hematology/ Oncology and Stem Cell Therapy, 2021, , .   | 0.9 | 3         |
| 70 | African American race as a risk factor associated with a second primary lung cancer after initial primary head and neck cancer. Head and Neck, 0, , .   | 2.0 | 3         |
| 71 | Immune checkpoint inhibitors: For how long do we need to release the brakes to achieve the optimum acceleration of immune-mediated anti-tumor response?. Oral Oncology, 2020, 101, 104435.  | 1.5 | 2         |
| 72 | p16 positive oropharyngeal small cell cancer: A case report. Oral Oncology, 2021, 121, 105391.  | 1.5 | 2         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 73 | ORIENT-31 as the Sakigake “Charging Samurai” Born of IMpower150 but Will MARIPOSA-2 IMPRESS in the “Meiji Modernization” of Post-3G EGFR TKI Progression?. Lung Cancer: Targets and Therapy, 2022, Volume 13, 13-21. | 2.7 | 2         |
| 74 | Generalizability of ORIENT-11 trial results to a US standard of care cohort with advanced non-small-cell lung cancer. Future Oncology, 2022, , .   | 2.4 | 2         |
| 75 | Clinical progress of KRAS-targeted therapies: what next?. Future Medicinal Chemistry, 0, , .   | 2.3 | 2         |
| 76 | Pan-cancer analysis of RNA expression of ANGIOTENSIN-I-CONVERTING ENZYME 2 reveals high variability and possible impact on COVID-19 clinical outcomes. Scientific Reports, 2021, 11, 5639.                           | 3.3 | 1         |
| 77 | Abstract 1058: Inhibition of nuclear transport protein XPO1 potentiates the effect of KRASG12C inhibitors. , 2021, , .   |     | 1         |
| 78 | Toxicities associated with checkpoint inhibitor immunotherapy: The Karmanos Cancer Center experience.. Journal of Clinical Oncology, 2017, 35, e14575-e14575.  | 1.6 | 1         |
| 79 | Radiation therapy and immune-related side effects in patients treated with PD-1 inhibitors.. Journal of Clinical Oncology, 2018, 36, 207-207.  | 1.6 | 1         |
| 80 | Controversies in lung cancer: heterogeneity in treatment recommendations for stage III NSCLC according to disease burden and oncogenic driver alterations. Clinical Lung Cancer, 2022, , .                           | 2.6 | 1         |
| 81 | Forget me not “ Incorporating standard chemotherapy in an exciting era of clinical trials. Oral Oncology, 2021, 116, 105160.   | 1.5 | 0         |
| 82 | A phase II trial of nintedanib in recurrent malignant pleural mesothelioma (MPM).. Journal of Clinical Oncology, 2019, 37, e20061-e20061.  | 1.6 | 0         |
| 83 | Deconstructing ADAURA. It is Not Yet Time to Forgo Platinum-based Adjuvant Chemotherapy in Resected Early Stage (IB-IIIa) EGFR-mutant NSCLC. Lung Cancer: Targets and Therapy, 0, Volume 13, 47-52.                  | 2.7 | 0         |